MedDataX Logo

Efficacy of Retinal Nerve Fiber Layer (RNFL) / Retinal Thickness Ratio by Cirrus OCT Utilizing Spectral -Domain Technology as a Diagnostic Predictor of Glaucoma

NCT ID: NCT00772993

Last Updated: 2008-10-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-10-31

Study Completion Date

2008-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Glaucoma is presumed to be an axonal disease which starts at the lamina cribrosa. This assumption has led to the monitoring of the retinal nerve fiber layer thickness for the diagnosis and monitoring of progression of glaucoma. However, varying disc size, myopia and tilted discs affect the thickness of the retinal nerve fiber layer. This study aims to ascertain the ration of the retinal nerve fiber layer against full retina as a predictor of glaucoma diagnosis and progression.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glaucoma Myopia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

glaucoma myopia myopia with glaucoma normal control

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Primary open angle glaucoma

No interventions assigned to this group

2

Normal Control

No interventions assigned to this group

3

Myopia with no evidence of glaucoma

No interventions assigned to this group

4

Myopia with evidence og glaucoma

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Primary open angle glaucoma
* Myopia
* Myopia with evidence of glaucoma
* Normal controls

Exclusion Criteria

* Evidence of retinal disease
* BCVA \< 0.4
* Secondary glaucoma due to intraocular inflammation
* Lens induced glaucoma
* Tumor induced glaucoma
* Neovascular glaucoma
Minimum Eligible Age

10 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Yonsei University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Institute of Vision Research, Department of Ophthalmology, Yonsei University School of Medicine, Severance Hospital.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Institute of Vision Research, Department of Ophthalmology, Severance Hospital, Yonsei University School of Medicine

Seoul, , South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Chan Yun Kim, MD,PhD.

Role: CONTACT

Phone: 82-2-2228-3570

Email: [email protected]

Sung Yong Kang, MD

Role: CONTACT

Phone: 82-2-2228-3570

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Chan Yun Kim, MD,PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

4-2008-0340

Identifier Type: -

Identifier Source: org_study_id